五氟丙酰衍生化-气相色谱/质谱联用法分析尿液中7-氨基硝西泮

目的用五氟丙酰衍生化-气相色谱/质谱联用法分析尿液中硝西泮的主要代谢物7-氨基硝西泮。方法尿液经乙醚萃取后,用五氟丙酰酸酐(PFPA)进行衍生化,得到7-氨基硝西泮衍生化物的总离子流色谱图和质谱图。结果根据7-氨基硝西泮衍生化物色谱的保留时间和质谱中主要特征离子的质荷比进行定性分析;用7-氨基氟硝西泮做内标,以7-氨基硝西泮和内标衍生化物定量离子的色谱峰面积比与浓度的关系进行定量分析。结论用五氟丙酰衍生化-GC/MS分析尿液中硝西泮的主要代谢物7-氨基硝西泮的方法定性、定量灵敏准确,测定结果可应用于司法鉴定。     

头发中氯硝西泮的分段分析在药物辅助犯罪案件中的作用

目的通过分段分析头发中的氯硝西泮,对药物辅助犯罪案件中受害人的摄药频度及摄药史进行推断。方法采用液氮冷冻研磨技术联合超声浴技术,以液相色谱-串联质谱法,对6名不同案件中受害人的头发分段分析,并测定各头发段中的氯硝西泮及7-氨基氯硝西泮的含量。结果 6名受害人的部分头发段中均检出氯硝西泮及其代谢物7-氨基氯硝西泮,且头发中药物峰值浓度的出现时间与受害人自述摄药时间相一致。结论头发分段分析可提供摄药频度与摄药时间信息,在药物辅助犯罪案件中具有独特的证据价值。     

氟硝西泮滥用及检测研究进展

具有镇静催眠作用的氟硝西泮曾在世界范围内被滥用,常被用于自杀、谋杀、迷奸、迷抢等案(事)件。近年其又成为俱乐部滥用药物之一。该药物在体内主要经肝脏代谢为7-氨基氟硝西泮和N-去甲基氟硝西泮,且7-氨基氟硝西泮的血药浓度常常大于血液中的母体药物浓度,大约90%的代谢产物经尿液排出,10%经粪便排出。目前报道的相关分析方法主要是对于血液、尿液、毛发、酒水饮品等检材经LLE、SPE、LPME等净化萃取后,采用毛细管电泳法、色谱法、质谱法及各种技术的联用,检测母体药物及相关代谢产物。本文对氟硝西泮的滥用、体内代谢以及样品的提取净化、仪器分析等进行总结,为相关案(事)件的办理提供参考。     

苯并二氮类药物及其主要代谢物的薄层色谱分析

目的建立饮料、血、尿中 11种常见苯并二氮类药物及尿中 7种主要代谢物的薄层色谱分析法(HPTLC)。方法分析物采用GDX10 1树脂进行固相萃取 ,乙醚作为洗脱溶剂。苯 :丙酮 (10∶6)等作为展开体系 ,改良碘化铋钾显色。结果所建方法绝对灵敏度 0 3～ 0 6μg,尿检出限 0 4～ 1 0 μg/ml、血检出限 0 6～ 1 0 μg/ml、饮料检出限 0 4～ 0 8μg/ml。结论HPTLC法简便、快速 ,适合作为常规毒物分析方法     

尿中地西泮及其代谢物的气相色谱电子捕获检测法分析

目的　建立尿中地西泮及其代谢物替马西泮、去甲西泮和奥沙西泮的GC/ECD分析方法。方法　尿样经β 葡萄糖醛酸酶水解后 ,用有机溶剂提取 ,再以N ,O 双三甲硅烷基三氟乙酰胺进行衍生化 ,衍生物用GC/ECD法分析。结果　检材中分析物的回收率 70 %以上 ,检出限 5ng/ml以下。结论　本法可进行口服地西泮 10mg人体 48h内尿液中地西泮代谢物的分析。     

尿中苯基脲类除草剂代谢物气相色谱分析

目的建立尿中苯基脲类除草剂代谢物的气相色谱分析方法。方法在检材中加入环己烷、固体氯化钠等试剂,分取有机相,在60℃水浴中加入衍生化试剂反应0．5h,冷却后洗去衍生化试剂,分取有机相进样进行气相色谱分析。结果尿中苯基脲类代谢物4一氯苯胺和3,4-二氯苯胺的检出限在5ng／mL以下,回收率良好,相对标准偏差均低于5％。在0．1μg～5μg／mL间线性关系良好。结论该法高效、灵敏、简便,适合对尿等生物检材中脲类除草剂的代谢物的定性和定量测定。     

尿中氯喹定性定量分析方法的研究

建立了人尿中氯喹的定性定量分析方法,2ml尿样用2ml×2环己烷：乙酸乙酯（8：2）提取净化后,60℃水浴室气吹干,残留物定容溶解后,气相色谱分析,氯喹的保留时间为9．44min。方法最低检测限为200ng／ml,回收率为87．0％,RSD＝7．9％（n＝5）,在0～50μg／ml浓度范围内,有良好的线性关系：A＝1778．9＋13686C,r＝0．999。方法同时可用于血中氯喹的分析。附一例应用报告,测得尿中氯喹的含量为0．745mg／ml,血中氯喹的含量为3．68μg／ml。尿液中同时检出氯喹的N－去单已基代谢物。定性结果经质谱法验证。     

SPE-HPLC/MS/MS法检测人唾液中地西泮及其代谢物

目的采用固相萃取-高效液相色谱-串联质谱法(SPE-HPLC/MS/MS)检测人唾液中地西泮及其代谢物。方法采用固相萃取法(SPE)处理唾液,HPLC/MS/MS法检测,MRM记录方式,保留时间和定性离子对定性,内标法和标准曲线法定量。结果地西泮及其代谢物去甲地西泮、去甲羟基西泮、去甲羟基地西泮葡萄糖醛酸苷(OG)、羟基地西泮葡萄糖醛酸苷(TG)的检测限在0.01ng/m L~0.5ng/m L之间,线性范围0.1ng/m L或0.5ng/m L~100ng/m L,回收率为84.9%~106%。口服5mg地西泮后15d内唾液中可检出地西泮及去甲西泮,但检出时间有个体差异,但去甲羟基西泮、TG和OG则不能检出。结论 SPE-HPLC/MS/MS检测法可应用于人唾液中地西泮及其代谢物的检测。人口服常量地西泮后唾液中可检出地西泮和去甲西泮,且检测窗口期较宽,但存在个体差异。     

根据三环类抗抑郁剂（TCA）原体的代谢物浓度比判断死因

本研究分别考察了 TCA 中毒和非 TCA 中毒(治疗剂量)死亡尸解肝、血的药物原体及代谢物浓度。在13例案件中,有9例如 TCA 过量引起的死亡,平均肝、血的药物浓度分别为0.02ug/g(SD176)和4.0ug/ml(SD1.9)。另外4例仅服治疗量的 TCA,死亡原因与 TCA 无关,其平均肝、血水平分别为29.0ug/g(SD10)和1.3ug/ml(SD0.4)。表1例出了超量和治疗量摄入 TCA,肝和血药物原体和主要代谢物浓度。表2例出了肝和血药物原体和代谢物浓度之比。     

QTRAP LC-MS/MS方法分析头发中氟胺酮及其代谢物的研究

目的建立头发中氟胺酮及其代谢物的液相色谱-四极杆/线性离子阱质谱(QTRAP LC-MS/MS)检测方法并分析头发样本中氟胺酮含量范围。方法将洗净的20mg头发样本加入2mL提取液研磨后超声提取,离心取上清液过滤膜后,采用多反应监测模式测定氟胺酮及其代谢物,并以该方法分析了50例样本中氟胺酮的含量。基于氟胺酮、氯胺酮结构的相似性,参考氯胺酮代谢物去甲氯胺酮的质谱裂解途径,对氟胺酮主要代谢物进行推断。结果氟胺酮在浓度范围0.004ng/mg～2ng/mg内线性良好;方法检出限为0.001ng/mg;在0.05、0.20、1.00 ng/mg 3个添加水平的回收率为90.2%～94.4%。50例阳性样本中氟胺酮含量在0.2ng/mg以上46例占比92%,含量最高值92.56ng/mg、平均值15.32ng/mg、中位值5.34ng/mg,反映了氟胺酮较为严重的滥用形势。结论本方法简便、高效、可靠,适用于头发中氟胺酮及其代谢物的鉴定。样本数据为氟胺酮列管后鉴定及阈值确定提供了参考。     

用气相色谱法/电子捕获检测器测定尿液中的三唑仑

建立了用气相色谱／电子捕获检测器测定尿液中三唑仑含量的方法。2ml尿样在破性条件下用2ml×2氯仿提取净化后,60℃水浴下用空气吹干,残留物用环己烷定容溶解后,进气相色谱仪分析,三唑仑的保留时间为10．74min。最低检测限为0．5ng／ml,回收率为95．98％,变异系数为7．85％（n＝5）。在2～50ng／ml浓度范围内有良好的线性关系：A＝－67．9＋570．IC,r＝0．9939。     

Fast confirmation of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH) in urine by LC/MS/MS using negative atmospheric-pressure chemical ionisation (APCI)

A fast method using automated solid-phase extraction (SPE) and short-column liquid-chromatography coupled to tandem mass-spectrometry (LC/MS/MS) with negative atmospheric-pressure chemical ionisation (APCI) has been developed for the confirmation of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH) in urine samples. This highly specific method which combines chromatographic separation and MS/MS-analysis can be used for the confirmation of positive immunoassay results with a NIDA cut-off of 15ng/ml. The conjugates of THC-COOH were hydrolysed prior to SPE, and a standard SPE was performed using C18-SPE columns. No derivatisation of the extracts was needed as in GC/MS analysis, and the LC run-time was 6.5min by gradient elution with a retention time of 2.4min. Linearity of calibration was obtained in the range between 0 and 500ng/ml (correlation coefficient R(2)=0.998). Using linear regression (0-50ng/ml) the limit of detection (LOD) was 2.0ng/ml and the limit of quantitation (LOQ) was 5.1ng/ml; day-to-day reproducibility and precision were tested at 15 and 250ng/ml and were 13.4ng/ml+/-3.3% and 255.8ng/ml+/-4.5%, respectively.     

Enzyme immunochemical detection of the use of hashish and confirmation by thin-layer chromatography

The EMIT cannabinoid assay was used for screening blood and urine after smoking tetrahydrocannabinol (THC; 10 mg) or ingestion of THC (30 mg). Cannabinoid levels in urine remain detectable up to 1 week. Confirmation was done by adsorption of the THC carboxylic acid onto a C18 extraction column and elution with acetone and TLC. The method is simple and sensitive and is applicable with common laboratory equipment. The detection limit is 10 ng/ml, using 10 ml urine.     

度冷丁滥用者尿中原体及其代谢产物的分析研究

本研究利用ＧＣ／ＭＳ（ＥＩ．ＰＣＩ）技术，在度冷丁滥用者尿中确认了６种代谢产物。并建立了ＧＣ／ＦＩＤ分析度冷丁及其代谢产物的方法。方法线性范围为０．１～２０μｇ／ｍｌ，变异系数小于１０％，最小检出量为５０ｎｇ／ｍｌ，适用于度冷丁成瘾者尿中含量的测定。     

The determination of clozapine in blood and urine by gas chromatography-mass spectrometry]

A method for measuring closapine in the blood and urine by gas chromatography-mass spectrometry as a trifluoroacetic derivative is proposed. The threshold level for closapine detection is 25 ng/ml in the blood and 30 ng/ml in the urine. Calibration curves are linear in the range 0.025-5 mcg/ml for the blood and 0.03-50 mcg/ml for the urine. The method can be used in forensic chemical and clinical toxicological analysis.     

Simultaneous analyses of cocaine, cocaethylene, and their possible metabolic and pyrolytic products

A method was developed for simultaneously analyzing cocaine (COC), benzoylecgonine (BZE), norbenzoylecgonine (BNE), norcocaine (NCOC), ecgonine (ECG), ecgonine methyl ester (EME), m-hydroxybenzoylecgonine (HBZE), anhydroecgonine methyl ester (AEME), cocaethylene (CE), norcocaethylene (NCE), and ecgonine ethyl ester (EEE) in blood, urine, and muscle. Available deuterated analogs of these analytes were used as internal standards. Proteins from blood and muscle homogenate were precipitated with cold acetonitrile. After the removal of acetonitrile by evaporation, the supernatants and urine were subjected to solid-phase extraction. The eluted analytes were converted to their hydrochloride salts and derivatized with pentafluoropropionic anhydride and 2,2,3,3,3-pentafluoro-1-propanol. The derivatized products were analyzed by a gas chromatograph (GC)/mass spectrometer by selected ion monitoring. The limit of detection (LOD) for COC, BZE, NCOC, EME, CE, NCE, and EEE was 2ng/ml, while the LODs for BNE, ECG, HBZE, and AEME were 25, 640, 50, and 13 ng/ml, respectively. This method was successfully applied in analyzing 13 case samples from aviation accident pilot fatalities and motor vehicle operators. AEME concentrations found in the 13 samples were consistent with those produced solely by the GC inlet pyrolysis of COC controls in blood. Anhydroecgonine cannot be used as a marker for the abuse of COC by smoking because it is also pyrolytically produced from COC metabolites on the GC inlet. The developed method can be effectively adopted for analyzing COC and related compounds in urine, blood, and muscle by a single extraction with increased sensitivity through formation of hydrochloride salts and using a one-step derivatization.     

Validation of a high performance liquid chromatographic method for alpha amanitin determination in urine

The objective of the present study was to develop and validate a liquid chromatographic method with electrochemical detection to measure alpha amanitin concentrations in urine after sample pretreatment with double mechanism (reversed phase/cation exchange) solid-phase extraction cartridges. The urine samples (10 ml) were purified and concentrated to 1 ml with elimination of matrix contaminants. The extracts were then separated by isocratic reversed-phase chromatography using a C18 column (4.6 mm×25 cm) with a mobile phase composed of 0.005 M phosphate buffer (pH 7.2) and acetonitrile (90:10). Coulometric detection was performed by applying an oxidation potential of +500 mV to a porous graphite electrode in a low-volume analytical cell. The limit of quantitation was 10 ng/ml with a signal-to-noise ratio=25. The linearity studied on spiked urine was satisfactory (r=0.9966) from 10 ng/ml to 200 ng/ml. The average extraction recovery of alpha amanitin was 78%, determined using spiked urine samples ranging from 10–300 ng/ml. The intra-assay precision was checked at 10, 50 and 100 ng/ml levels (n=10) in spiked urine samples, with resulting coefficients of variation of 3.6%, 2% and 1.5%, respectively.     

Comparison of daily urine,sweat, and skin swabs among cocaine users

This study (1) compares urine, skin swabs, and PharmChek sweat patches for monitoring drug use; (2) measures possible environmental contamination in recent cocaine (COC) users; and (3) evaluates various immunoassays (IA) for screening COC in diverse matrices. Unique aspects include daily urine monitoring of 10 participants for 4 weeks, multiple monitoring methods, analysis for all specimens by IA and gas chromatography (GC)/mass spectrometry (MS), and the potential for continued illicit drug use by participants. Urine served as the "gold standard" specimen for determining drug use. Only cocaine and related substances were detected.Trace amounts of drugs were found on the skin (<50 ng per swab) of urine-negative participants' hands or forehead. In contrast, larger quantities of COC were found on the skin of individuals with BE-positive urines or individuals living with drug users (up to 20 microg per swab). Patch COC amounts among the three regular users (250-9000, 0-240, 160-22,000 ng per patch) exceeded BE (50-950, none, 30-2200 ng per patch). Pre-swabs, valuable for interpreting the source or time frame of positive patch results, contained substantial COC (38-1160, 0-152, 34-762 ng per swab) prior to patch application; therefore, patch results may represent current use, prior use, contamination, or a combination. In three individuals with no indication of cocaine use, false positives (defined as sweat patch positive when urine specimens were <300ng BE/ml) occurred at a 7% rate. Proposed cut-off concentrations of 75 ng cocaine per patch and 300 ng BE/ml urine curtail the incidence of false positives in this limited population. Three immunoassays were compared to screen specimens for cocaine: a modified, manual Microgenics CEDIA; a Cozart ELISA; and an OraSure ELISA. CEDIA's limit of detection (LOD) was 81ng/ml, compared with LODs of 4 ng/ml for the Cozart ELISA and 1.5 ng/ml for the OraSure ELISA. Cozart correlated with OraSure results for COC concentrations <2000 ng per swab (n=117), r(2)=0.79.     

尿中氯胺酮及其代谢物检测的研究

目的建立氯胺酮滥用者尿中氯胺酮及其代谢物检测方法。方法尿液用有机溶剂液-液萃取,气相色谱/氮磷检测器、电子捕获检测器、氢火焰检测器和气-质联用仪测定。结果确认了尿液中氯胺酮的主要代谢物,尿液中氯胺酮及去甲氯胺酮的最小检测限均为2ng/mL,脱氢去甲氯胺酮的最小检测限为5ng/mL。结论所建方法快速、灵敏、准确,能够满足氯胺酮滥用者尿液检测的需要。